Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study

Weis, Sebastian; Scherag, André; Baier, Michael; Kiehntopf, Michael; Kamradt, Thomas; Kolanos, Steffi; Ankert, Juliane; Glöckner, Stefan; Makarewicz, Oliwia; Hagel, Stefan; Bahrs, Christina; Kimmig, Aurelia; Proquitté, Hans; Guerra, Joel; Rimek, Dagmar; Löffler, Bettina; Pletz, Mathias W.; Hotz, Thomas; Partners, Local Cooperation; Enders, Petra; Koch, Renate; Mai, Steffen; Ullrich, Matthias; Richert, Cora; Eibner, Cornelius; Meinung, Bettina; Stötzer, Kay; Köhler, Julia R.; Cipowicz, Hans; Pinkwart, Christine; Bauer, Michael; Dickmann, Petra; Licht, Annika; Scholz, Juliane; Wetzker, Wibke; Hartung, Anita; Weiß, Daniel L.; Thieme, Lara; Hanf, Gabi; Schnizer, Clara; Müller, Jasmin; Kosenkow, Jennifer; Röstel, Franziska; Andreas, Nico; Marquardt, Raphaela; Deinhardt‐Emmer, Stefanie; Kühn, Sebastian

doi:10.1016/j.cmi.2020.11.009

Cited by 28 publications

(50 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of this seroprevalence analysis showed a positivity rate among individuals assisted by the internal healthcare system of the Vatican City State lower than that found in other studies on similar samples ( 7 , 8 , 9 , 10 ). This may be due to the small sample size and to the low number of COVID-19 cases tracked in the Vatican City State thanks to the control and prevention measures taken by the Directorate of Health and Hygiene.…”

contrasting

confidence: 78%

SARS-CoV-2 seroprevalence in the Vatican City State

Ralli

Arcangeli

Soave

et al. 2021

European Journal of Internal Medicine

View full text Add to dashboard Cite

contrasting

confidence: 78%

SARS-CoV-2 seroprevalence in the Vatican City State

Ralli

Arcangeli

Soave

et al. 2021

European Journal of Internal Medicine

View full text Add to dashboard Cite

“…Positive serologic testing was 1.5 to 8.1 times more likely in people who had had any acute respiratory infection (ARI) symptoms; for the individual symptoms this ranged from 2-fold (fever) to 46-fold (loss of smell and taste). Three studies also reported prevalence of other non-specific symptoms such as headache, chest pain, skin rash, nausea, and fatigue among the participants [ 17 , 24 , 30 ].…”

Section: Resultsmentioning

confidence: 99%

“…The major reason for exclusion was high risk of bias in the selection of participants (Full list of excluded studies in S1 Table ). Seventeen articles-4 preprints, 11 published studies, and 2 government reports-from 15 countries (Argentina, Brazil, Spain, Hungary, Germany, Luxembourg, Switzerland, Denmark, Sweden, Finland, Iceland, the United States of America (USA), the Channel Islands, Iran, and Japan) that tested a combined total of 118,297 participants met eligibility criteria [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. (Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…Further details on the study adjustment details and sources for cumulative incidence data are provided in S2 Table . The cumulative incidence rates at the regional levels (red squares and diamonds) ranged from 0.006% in Utsunomiya, Tokyo [18] to 9.22% in Barrio Mugica slum of Buenos Aires, Argentina [14]. The calculated cumulative case incidence for regions imputed from reported COVID-19 deaths (assuming true CFR of 1%, brown crosses) ranged from 0.09% in Rio Grande do Sul, Brazil [23] to 33.98% in Neustadt-am-Rennsteig, Germany [30]. The data collection timeframes of the included studies are shown in S1 Fig in relation to the rolling 7-day average of confirmed cases in each country.…”

Section: Seroprevalencementioning

confidence: 99%

See 1 more Smart Citation

Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review

et al. 2021

View full text Add to dashboard Cite

Background Accurate seroprevalence estimates of SARS-CoV-2 in different populations could clarify the extent to which current testing strategies are identifying all active infection, and hence the true magnitude and spread of the infection. Our primary objective was to identify valid seroprevalence studies of SARS-CoV-2 infection and compare their estimates with the reported, and imputed, COVID-19 case rates within the same population at the same time point. Methods We searched PubMed, Embase, the Cochrane COVID-19 trials, and Europe-PMC for published studies and pre-prints that reported anti-SARS-CoV-2 IgG, IgM and/or IgA antibodies for serosurveys of the general community from 1 Jan to 12 Aug 2020. Results Of the 2199 studies identified, 170 were assessed for full text and 17 studies representing 15 regions and 118,297 subjects were includable. The seroprevalence proportions in 8 studies ranged between 1%-10%, with 5 studies under 1%, and 4 over 10%—from the notably hard-hit regions of Gangelt, Germany; Northwest Iran; Buenos Aires, Argentina; and Stockholm, Sweden. For seropositive cases who were not previously identified as COVID-19 cases, the majority had prior COVID-like symptoms. The estimated seroprevalences ranged from 0.56–717 times greater than the number of reported cumulative cases–half of the studies reported greater than 10 times more SARS-CoV-2 infections than the cumulative number of cases. Conclusions The findings show SARS-CoV-2 seroprevalence is well below “herd immunity” in all countries studied. The estimated number of infections, however, were much greater than the number of reported cases and deaths in almost all locations. The majority of seropositive people reported prior COVID-like symptoms, suggesting that undertesting of symptomatic people may be causing a substantial under-ascertainment of SARS-CoV-2 infections.

show abstract

“…33 However, the humoral response to SARS-CoV-2 appears to be proportional to COVID-19 severity: the highest antibody titres are detected in severe and protracted cases, compared with low or undetectable titres in patients with mild or asymptomatic COVID-19. 34 The magnitude of the antibody response often correlates with T-cell responses, although uncoupled responses with strong specific T-cell production and no antibody production have been described. 35 SARS, MERS, and COVID-19 have a similarly short-lived humoral antibody response.…”

Section: Clinical Pathology Of Covid-19mentioning

confidence: 99%

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

Osuchowski

Winkler

Skirecki

et al. 2021

The Lancet Respiratory Medicine

Self Cite

421

364

View full text Add to dashboard Cite

The zoonotic SARS-CoV-2 virus that causes COVID-19 continues to spread worldwide, with devastating consequences. While the medical community has gained insight into the epidemiology of COVID-19, important questions remain about the clinical complexities and underlying mechanisms of disease phenotypes. Severe COVID-19 most commonly involves respiratory manifestations, although other systems are also affected, and acute disease is often followed by protracted complications. Such complex manifestations suggest that SARS-CoV-2 dysregulates the host response, triggering wide-ranging immuno-inflammatory, thrombotic, and parenchymal derangements. We review the intricacies of COVID-19 pathophysiology, its various phenotypes, and the anti-SARS-CoV-2 host response at the humoral and cellular levels. Some similarities exist between COVID-19 and respiratory failure of other origins, but evidence for many distinctive mechanistic features indicates that COVID-19 constitutes a new disease entity, with emerging data suggesting involvement of an endotheliopathy-centred pathophysiology. Further research, combining basic and clinical studies, is needed to advance understanding of pathophysiological mechanisms and to characterise immuno-inflammatory derangements across the range of phenotypes to enable optimum care for patients with COVID-19. Equipe d'Accueil 7426,

show abstract

Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study

Cited by 28 publications

References 26 publications

SARS-CoV-2 seroprevalence in the Vatican City State

SARS-CoV-2 seroprevalence in the Vatican City State

Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

Contact Info

Product

Resources

About